Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

117%

7 of 6 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 3

5(71.4%)

Phase 2

1(14.3%)

Phase 1

1(14.3%)

7Total

Phase 3(5)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04553068Phase 3Completed

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

Role: lead

NCT01306331Phase 3Completed

Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel

Role: lead

NCT02693418Phase 1Completed

Duration of Effect of Acidform Gel on Vaginal pH

Role: lead

NCT03243305Phase 3Completed

AMP002 Phase III Contraceptive Study

Role: lead

NCT03107377Phase 2Completed

Phase 2B/3 Double-blinded Placebo-controlled

Role: lead

NCT02483533Phase 3Terminated

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Role: lead

NCT02398188Phase 3Completed

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

Role: lead

All 7 trials loaded